Clinical review 102: Type 2 diabetes mellitus: Update on diagnosis, pathophysiology, and treatment

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 4, 1999, Pages 1165-1171

  Mahler, Richard J ^a   Adler, Michael L ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; INSULIN; SULFONYLUREA;

B LYMPHOCYTE; DISEASE CLASSIFICATION; EXERCISE; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0033323822     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.84.4.5612     Document Type: Review

References (124)

1. Management of diabetes from a public health perspective
2. The effect of intensive treatment of diabetes in the development and progression of long-term complications in insulin-dependent diabetes mellitus
3. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
4. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
5. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38)
6. Heart disease and diabetes
7. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
8. Cholesterol lowering in the management of coronary artery disease: The clinical implications of recent trials
9. Coronary heart disease in NIDDM patients in the Helsinki heart study
10. Diabetes and hypertension
11. Report of the expert committee on the diagnosis and classification of diabetes mellitus
12. Glucose tolerance and mortality, including a substudy of tolbutamide treatment
13. The clinical implications of impaired glucose tolerance
14. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone
15. The role of insulin resistance in human disease
16. Pathogenesis of non-insulin dependent diabetes (type 2)
17. Clinical aspects of islet B cell function in non-insulin dependent diabetes mellitus
18. Natural history of B-cell dysfunction in NIDDM
19. B cells in type 2 diabetes mellitus
20. Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans
21. Effect of sulphonylureas on glucose-stimulated insulin secretion in healthy and non-insulin-dependent diabetes subjects: A dose response study
22. Metabolic signaling of insulin secretion
23. Hyperproinsulinemia and amyloid in NIDDM: Clues to etiology of islet B cell dysfunction?
24. Impaired pulsatile secretion of insulin in relatives of patients with non-insulin dependent diabetes mellitus
25. Early metabolic defects in persons at increased risk of non-insulin dependent diabetes mellitus
26. Insulin secretion, insulin action and hepatic glucose production in identical twins discordant for non-insulin dependent diabetes mellitus
27. Slow glucose removal rate and hyperinsulinemia precede the development of type 2 diabetes in the offspring of diabetic parents
28. Metabolic and genetic characterization of prediabetic states
29. Genetic susceptibility to non-insulin dependent diabetes mellitus
30. Insulin secretion and sensitivity in women fulfilling WHO criteria for gestational diabetes mellitus
31. Glucokinase as pancreatic B cell glucose sensor and diabetes gene
32. Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations
33. Cellular and molecular mechanism of non-insulin dependent diabetes mellitus
34. How does glibenclamide lower glucose concentration in patients with type 2 diabetes?
35. Immunoassay of endogenous plasma insulin in man
36. Insulin resistance vs. insulin deficiency in non-insulin dependent diabetes mellitus: Problems and prospects
37. The genetic basis of type 2 diabetes mellitus: Impaired insulin secretion vs. impaired insulin sensitivity
38. Sensitivity of insulin secretion to feedback inhibition by hyperinsulinemia
39. Effect of sustained physiologic hyperinsulinemia and hyperglycemia on insulin secretion and insulin sensitivity in man
40. Hyperglycemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: Implications for the management of diabetes
41. Evidence that glucose transport is rate-limiting for in-vivo glucose uptake
42. Glucose toxicity
43. Different etiologies of type 2 (non-insulin dependent) diabetes mellitus in obese and non obese subjects
44. Health risk of obesity
45. Abdominal obesity and the development of non-insulin dependent diabetes mellitus
46. Abdominal fat and insulin resistance in normal and overweight women: Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM
47. Primary insulin resistance: A risk syndrome
48. Fasting hyperinsulinemia and cardiovascular risk factors in non-diabetic adults: Stronger associations in lean vs. obese subjects
49. The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: Results of the Paris prospective study
50. The cardiovascular dysmetabolic syndrome
51. Insulin resistance with respect to lipolysis in non-diabetic relative of European patients with type 2 diabetes
52. The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents
53. Decreased insulin activation of glycogen synthase in skeletal muscles of young non-obese Caucasian first-degree relatives of patients with non-insulin dependent diabetes mellitus
54. Decreased tyrosine kinase activity in partially purified insulin receptors from muscle of young, non-obese first-degree relatives of patients with type 2 (non-insulin dependent) diabetes mellitus
55. Pancreatic β-cell dysfunction as the primary genetic lesion in NIDDM
56. Impaired pulsatile secretion of insulin in relatives of patients with non-insulin dependent diabetes
57. Renal glucose production and utilization: New aspects in humans
58. Diet therapy of type 2 diabetes mellitus
59. Diet therapy in diabetes mellitus: Is there a single best diet?
60. Use of very low-calorie diet in the treatment of obese persons with non-insulin dependent diabetes mellitus
61. Benefits and limitations of very low calorie diet therapy in obese NIDDM
62. Rate of weight gain, weight fluctuation, and incidence of NIDDM
63. Weight control: Metabolic and cardiovascular effects
64. Nutrition principles in the management of diabetes and related complications
65. Effects of dietary fiber and carbohydrate on glucose and lipoprotein metabolism in diabetic patients
66. Prevention of non-insulin diabetes mellitus with physical activity
67. Physical activity and incidence of non-insulin dependent diabetes mellitus in women
68. Glucose metabolism during physical exercise in patients with non-insulin dependent (type 2) diabetes
69. Prevention of type 2 (non-insulin dependent) diabetes mellitus by diet and physical exercise
70. Resistance training in the treatment of non-insulin dependent diabetes mellitus
71. Exercise in the management of type 2 diabetes mellitus
72. The mechanism of action of the hypoglycemic sulfonamides: A concept based on investigations in animals and human beings
73. + channels
74. Special pharmacology of the new sulphonylurea glimepiride
75. Comparison of efficacy, secondary failure rate, and complications of sulphonylureas
76. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes
77. Clinical biostatistics. VIII. An analytical appraisal of the University Group Diabetes Program (UGDP) study
78. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: A mixed blessing?
79. Cardiovascular effects of sulphonylurea derivatives. Implications for the treatment of NIDDM?
80. UK prospective diabetes study 16. Overview of 6 years therapy of type 2 diabetes: A progressive disease
81. Effect of a new oral hypoglycemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM
82. Additional treatment with repaglinide provides significant improvement in glycemic control in NIDDM patients poorly controlled on metformin
83. Metformin: Actions and indications for use in non-insulin dependent diabetes mellitus
84. Comparison of chlorpropamide and metformin treatment on weight and blood glucose response of uncontrolled obese diabetes
85. Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia in man
86. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients
87. Combined sulphonylureabiguanide therapy for non-insulin dependent diabetes metabolic effects of glibenclamide and metformin and phenformin in newly diagnosed obese patients
88. Metformin
89. An overview of metformin in the treatment of type 2 diabetes mellitus
90. Biguanide associated lactic acidosis
91. Reduction of insulin resistance in obese and/or diabetic animals by 3-4-(1-methylcyclohexylmethoxy)-benzyl-thiazolidine 2,4-dione (ADD-3870, U-63, 287, ciglitazone), a new antidiabetic agent
92. Thiazolidinediones
93. Studies in hindered phenols and analogues. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation
94. PPAR-γ: Adipogenic regulator and thiazolidinedione receptor
95. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome-proliferator-activated receptor γ
96. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone
97. Thiazolidinediones in the treatment of insulin resistance and type 2 diabetes
98. Effect of troglitazone in insulin-treated patients with type 2 diabetes mellitus
99. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients
100. Efficacy and metabolic effects of metformin and troglitazone in type 2 diabetes mellitus
101. Hepatic dysfunction associated with troglitazone
102. A novel antidiabetic drug, troglitazone. Reason for hope and concern
103. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM
104. α-Glucosidase inhibitors
105. Insulins
106. Insulin Lispro
107. (Lys(B28)Pro(B29)) human insulin: A rapidly absorbed analogue of human insulin
108. Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions
109. Hyperinsulinemia as an independent risk factor for ischemic heart disease
110. Exogenous insulin administration and cardiovascular risk in NIDDM and IDDM
111. Is insulin really a heart disease risk factor?
112. Intestinal factors in the control of insulin secretion
113. Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. A physiologic role of glucagon-like peptide 1
114. Human studies with glucagon-like-peptide-1: Potential of the gut hormone for clinical use
115. Glucagonostatic and insulinotropic action of glucagon like peptide 1-(7-36) amide
116. Glucagon-like peptides
117. The amylin analogue pramlintide decreases post-prandial plasma glucose and glucagon in IDDM
118. Effect of amylin and the amylin agonist pramlintide on glucose metabolism
119. Amylin and glycaemic regulation: A possible role for the human amylin analogue pramlintide
120. Does recombinant human insulin-like growth factor-1 have a role in the treatment of diabetes?
121. Randomized placebo-controlled trial of human recombinant insulin-like growth factor 1 plus intensive insulin therapy in adolescents with insulindependent diabetes mellitus
122. Standards of medical care for patients with diabetes mellitus
123. The effects of improved glycemic control in complications in type 2 diabetes